Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
FAST NEWS: RemeGen scales back A-share fundraising plan
The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
PODCAST: China’s Burgeoning Debt, and a New Type of China IPO
By Doug Young & Rene Vanguestaine China's debt-to-GDP ratio swelled to 288% last year, up 13.5 basis points and a huge level by any standard. Is this kind of debt…
FAST NEWS: Hutchmed swings to profit on strong revenue growth
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced Monday a net profit of $169 million in the first half of 2023, reversing a loss of $163 million in the same period…
FAST NEWS: Nomura takes up Kintor Pharma stake
The latest: Japanese financial group Nomura Holdings disclosed it purchased 5.91 million shares of Kintor Pharmaceutical Ltd. (9939.HK) on Jun. 1, raising its stake in the biotech company from 4.06% to 5.39%,…
FAST NEWS: BeiGene Loss Narrows on Brisk Sales for Core Products
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Monday its revenue rose 20.4% last year to $1.42 billion, thanks to big increases from its two core products,…
Recent Articles
FAST NEWS: RemeGen scales back A-share fundraising plan
9995.HK
688331.SHG
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US
6160.HK
688235.SHG
RELATED ARTICLES
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK -
Innovent ditches low-value stake sale after investor outcry
1801.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
